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Summary
Background.  —  The  role  of  implantable  loop  recorders  (ILRs)  in  the  evaluation  strategy  for
recurrent syncope  in  France  is  limited  by  lack  of  knowledge  of  the  cost.
Aim. —  To  compare  a  conventional  evaluation  strategy  for  syncope  with  the  early  use  of  an  ILR
in low-risk  patients,  in  terms  of  diagnostic  yield,  cost  and  impact  on  quality  of  life  (QoL).
Methods.  —  National  prospective  randomized  open-label  multicenter  study  of  patients  with  a
single syncope  (if  severe  and  recent)  or  at  least  two  syncopes  in  the  past  year.
Results.  —  Seventy-eight  patients  (32  men)  were  randomized  to  the  ILR  strategy  (ILR  group,
n =  39)  or  the  conventional  evaluation  strategy  (CONV  group,  n  =  39):  mean  age  66.2  ±  14.8  years;
4.3 ±  6.4  previous  syncopes.  After  14  months  of  follow-up,  a  certain  cause  of  syncope  was
established  in  18  (46.2%)  patients  in  the  ILR  group  and  two  (5%)  patients  in  the  CONV  group
(P <  0.001).  Advanced  cardiological  tests  were  performed  less  frequently  in  the  ILR  group  than
in the  CONV  group  (0.03  ±  0.2  vs.  0.2  ±  0.5  tests  per  patient;  P  =  0.05).  Patients  in  the  ILR
group were  hospitalized  for  a  non-signiﬁcantly  shorter  period  than  patients  in  the  CONV  group
(5.7 ±  3.2  vs.  8.0  ±  1.4  days).  There  was  no  difference  between  the  two  groups  in  terms  of  QoL
main composite  score.
Conclusion.  —  In  patients  with  unexplained  syncope,  the  early  use  of  an  ILR  has  a  superior
diagnostic  yield  compared  with  the  conventional  evaluation  strategy,  with  lower  healthcare-
related costs.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’utilisation  des  enregisteurs  électrocardiographiques  implantables  (EEI)  dans  le
diagnostic des  syncopes  se  heurte  encore  en  France  à  des  incertitudes  médico-économiques.
But. —  Comparer  la  rentabilité  diagnostique,  le  coût  et  l’impact  sur  la  qualité  de  vie  d’une
stratégie conventionnelle  par  rapport  à  l’utilisation  précoce  du  EEI  chez  des  patients  ayant  des
syncopes inexpliquées  et  étant  à  faible  risque  d’événement  cardio-vasculaire  grave.
Méthode.  — Étude  nationale,  multicentrique,  prospective,  randomisée  et  ouverte  chez  des
patients ayant  fait  soit  1  seule  syncope  grave  et  récente,  soit  au  moins  2  syncopes  au  cours
de la  dernière  année.
Résultats.  — Soixante-dix-huit  patients  ont  été  randomisés  entre  le  groupe  EEI  (39  patients)  et
le groupe  conventionnel  (CONV)  (39  patients)  :  32  hommes,  âgés  de  66,2  ±  14,8  années,  ayant
déjà présenté  4,3  ±  6,4  syncopes.  Après  14  mois  de  suivi,  un  diagnostic  de  certitude  a  pu  être
posé chez  18  patients  (46,2  %)  du  groupe  EEI  et  seulement  2  (5  %)  du  groupe  CONV  (p  <  0,001).  Le
recours aux  examens  complémentaires  cardiologiques  sophistiqués  a  été  moins  fréquent  dans
le groupe  EEI  (0,03  ±  0,2  vs  0,2  ±  0,5  examen  par  patient  ;  p  =  0,05).  Nous  n’avons  pas  noté  de
différence  signiﬁcative  entre  les  2  groupes  pour  les  scores  globaux  de  qualité  de  vie.
Conclusion.  —  Cette  étude  montre  que,  dans  le  contexte  du  système  de  soins  franc¸ais,
l’utilisation  précoce  du  MEI  chez  les  patients  présentant  des  syncopes  inexpliquées  et  à  bas
risque d’événement  cardio-vasculaire  grave  est  plus  efﬁcace  et  moins  coûteuse  que  la  stratégie
conventionnelle,  sans  impact  signiﬁcatif  sur  la  qualité  de  vie.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Syncope  is  a  common  condition,  affecting  3.5%  of  the  popu-
lation,  and  is  recurrent  in  30%  of  cases.  Identiﬁcation  of  the
cause  leads  to  the  most  effective  treatment.  However,  after
an  often-complex  and  non-standardized  diagnostic  process,
no  cause  is  identiﬁed  in  13—42%  of  cases  [1].
The  implantable  loop  recorder  (ILR)  is  now  part  of  our
practice  and  its  use  is  recommended  very  early  in  the  diag-
nostic  process  in  low-risk  patients  [1].  However,  the  precise
determination  of  its  role  in  the  evaluation  strategy  for  recur-
rent  syncope  in  France  is  limited  by  lack  of  knowledge  of  the
cost.
W
tThe  aims  of  this  French  Study  on  implantable  Holter
ecorders  in  syncope  (FRESH)  were  to  compare  the  diag-
ostic  yield  and  costs  of  a  common  evaluation  strategy  for
yncope  with  the  early  use  of  an  ILR  in  low-risk  patients,  and
o  analyse  the  quality  of  life  (QoL)  associated  with  the  two
trategies.
ethods
tudy populatione  included  all  consecutive  patients  from  the  hospitaliza-
ion  ward  or  outpatient  department  who  presented  with  one
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f  the  following  criteria:  a  single  syncope,  if  severe  (i.e.
ot  preceded  by  prodrome,  which  resulted  in  an  injury)  and
ecent  (i.e.  occurring  within  the  previous  six  months);  or
t  least  two  syncopes  in  the  past  12  months.  The  syncope
ad  to  remain  unexplained  at  the  end  of  the  clinical  exami-
ation,  and  after  performing  a  12-lead  electrocardiogram
ECG),  echocardiography  and  head-up  tilt-test,  meaning
hat  a  further  diagnostic  workup  was  mandatory.  The  exclu-
ion  criteria  were  as  follows:  signiﬁcant  heart  disease  (i.e.
eft  ventricular  ejection  fraction  <  40%);  a  history  of  myocar-
ial  infarction  or  unstable  coronary  artery  disease;  a history
f  arrhythmia;  potentially  arrhythmogenic  drug  use;  a  family
istory  of  sudden  death;  presence  of  bifascicular  intraven-
ricular  conduction  disturbance  on  the  ECG;  hypertrophic
ardiomyopathy  with  or  without  obstruction;  and  aortic
tenosis.  Patients  provided  written  informed  consent  to  par-
icipate  in  the  study.  Institutional  review  board  approval  was
btained  at  all  study  sites.
tudy design
his  national  prospective  randomized  open-label  multi-
enter  study  included  a  representative  sample  of  French
cademic  and  non-academic  hospitals.
Included  patients  were  randomized  either  to  receive  an
LR  (Reveal® or  Reveal® Plus,  Medtronic  Inc.,  Minneapolis,
N,  USA)  immediately  (ILR  group)  or  to  be  investigated
ccording  to  the  conventional  evaluation  strategy  commonly
sed  by  the  attending  physician,  with  exclusion  of  the  use
f  an  ILR  (CONV  group).  By  protocol,  the  ﬁnal  diagnosis,
hether  ECG-documented  or  not,  was  left  to  the  investi-
ator.
Patients  were  randomly  allocated  into  the  CONV  and  ILR
roups  using  a  computer-generated  randomization  list.  The
atients  were  followed  for  a  period  of  14  months,  with
utpatient  consultations  scheduled  at  two,  six,  10  and  14
onths  in  the  ILR  group  and  at  six  and  14  months  in  the  CONV
roup.  As  these  visits  were  performed  only  for  the  purpose
f  the  study,  they  were  not  entered  into  the  cost  analysis.
n  both  arms,  non-scheduled  consultations  were  performed
f  necessary  and  were  entered  into  the  cost  analysis.
ost analysis
o  evaluate  the  economic  burden  on  healthcare  providers,
e  assessed  the  duration  of  the  hospitalizations  and  the
umber  of  different  consultations  and  medical  tests  per-
ormed.  The  costs  were  assessed  based  on  the  number  of
ospitalization  days  and  the  number  of  consultations  or
ests,  to  put  the  analysis  in  the  context  of  society.  Of  note,
he  cost  of  the  ILR  was  not  included  in  the  cost  analysis  as
t  was  not  reimbursed  at  that  time  in  France.
Consultations  were  deﬁned  as  physician  visits  accord-
ng  to  the  French  care  system,  done  by  the  general
ractitioner  (GP)  or  a  specialist  (cardiologist,  neurolo-
ist  or  other  specialist).  We  identiﬁed  four  categories  of
ests,  as  follows:  standard  cardiological  tests  (12-lead  ECG,
ransthoracic  echocardiography,  24-hour  Holter  monitoring,
ead-up  tilt  test);  advanced  cardiological  tests  (tran-
oesophageal  echocardiography,  electrophysiological  study,
arotid  ultrasound,  ambulatory  blood  pressure  monitoring,
readmill  test,  coronary  angiography);  neurological  tests
(
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electroencephalogram,  brain  computed  tomography  scan);
nd  any  other  tests  (blood  sampling,  chest  X-ray,  any  other
on-detailed  tests).
For  the  tests  listed  above,  the  cost  unit  was  the  total
umber  of  examinations  performed.  This  arbitrary  listing
rovides  a  plausible  order  of  magnitude.
uality-of-life analysis
n  analysis  of  QoL  using  the  36-Item  Short  Form  Health  Sur-
ey  (SF-36)  questionnaire  was  performed  at  baseline,  six
onths  and  the  end  of  the  study.  The  SF-36  questionnaire
s  a  self-administered  questionnaire  that  measures  health
n  eight  multi-item  dimensions,  covering  functional  status,
ell-being  and  overall  evaluation  of  health  [2].
tatistical analysis
nalysis  was  by  intention-to-treat.  Variables  are  expressed
s  mean  ±  standard  deviations.  Comparisons  were
ade,  where  appropriate,  by  Fisher’s  exact  test  or
he  Mann—Whitney  U  test.
Diagnosis  efﬁcacy  was  compared  between  the  two  meth-
ds.  An  analysis  based  on  the  comparison,  by  volume,  of  the
arious  tests  for  each  of  the  different  diagnostic  methods
as  performed.
Regarding  the  number  of  patients  to  include,  a
reliminary  study  (not  published)  showed  that  the  cost-
ffectiveness  ratio  (CER)  using  the  conventional  strategy
or  a  patient  referred  for  syncope  to  our  department  was
 9336/percentages  of  diagnosis,  and  that  the  relative  CER
as  D  12,195/percentages  of  diagnosis.  We  considered  that
he  variance  of  the  costs  and  effectiveness  would  be  iden-
ical  with  both  methods,  with  a magnitude  effect  of  1.
ssuming  a  bilateral  situation,  with  a  power  of  80%  and  a
ype  I  error  risk  of  5%,  a  sample  of  35  patients  was  neces-
ary  in  each  group  to  detect  an  effect  size  of  30%.  In  view
f  losses  to  follow-up  and  dropouts,  the  sample  size  was
ncreased  by  10%,  resulting  in  a  requirement  for  77  patients
o  be  included  in  the  study.
esults
etween  April  2004  and  August  2008,  79  patients  met  the
nclusion  criteria  in  13  centres  in  France  and  were  screened
or  randomization;  one  patient  withdrew  his  consent  imme-
iately  after  being  screened  and  was  therefore  excluded
rom  the  study.
Of the  78  patients,  39  were  randomized  to  receive  an
LR  and  39  were  randomized  to  the  conventional  evaluation
trategy.  According  to  local  practice  in  each  centre,  patients
llocated  to  the  ILR  group  were  implanted  6.6  ±  9.5  days
fter  randomization.
The  demographic  and  clinical  characteristics  of  patients
re  presented  in  Table  1. All  of  the  patients  were  in
inus  rhythm,  except  for  two  patients  who  were  in  atrial
brillation.  The  PR  interval  duration  was  168.1  ±  22.9  ms
range  120—230  ms)  and  the  QRS  complex  was  normal  in  73
atients;  four  patients  presented  with  isolated  right  bundle
ranch  block  and  one  had  isolated  left  anterior  haemi-
lock.  The  patients  had  no  heart  disease  that  could  explain
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Table  1  Patient  characteristics.
ILR  CONV  P
(n  =  39)  (n  =  39)
Men  18  (46)  14  (36)  0.49
Age  (years)  67.6  ±  13.7  64.8  ±  15.8  0.40
Age  ≥  70  years  22  (56)  15  (38)  0.17
History  of  syncope  (years)  2.5  ±  4.6  4.4  ±  8.9  0.32
Inclusion  after  one  severe  recent  syncope 7  (18) 14  (36) 0.12
Total  number  of  syncopes  (n) 4.6  ±  8.2 4.1  ±  3.9 0.71
Number  of  syncopes  in  the  last  6  months  (n) 2.2 ±  2.5 1.8  ±  2.0 0.24
Traumatic  syncope  20  (51)  20  (51)  1.0
Syncope  with  jerking  movements  2  (5)  1  (3)  1.0
Previous  admission  for  syncope  17  (44)  8  (20)  0.05
Heart  disease  17  (44)  12  (31)  0.34
Systemic  hypertension  5  (13)  4  (10)
Coronary  artery  disease  5  (13)  6  (15)
Valvular  heart  disease  2  (5)  2  (5)
Other  5  (13)  0  (0)
Data are number (%) or mean ± standard deviation. CONV: conventional evaluation; ILR: implantable loop recorder.
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psyncope  and  the  mean  left  ventricular  ejection  fraction  was
64.3  ±  7.4%  (range  45—82%).
Follow-up
After  14  months  of  follow-up,  a  certain  cause  of  syncope
was  established  in  18  (46.2%)  patients  in  the  ILR  group  and
two  (5%)  patients  in  the  CONV  group  (P  <  0.001),  demon-
strating  a  highly  improved  diagnostic  performance  in  the  ILR
group.  The  causes  of  syncope  in  both  groups  are  presented
in  Table  2.  In  the  CONV  group,  at  the  end  of  the  workup,  the
supposed  aetiology  was  reﬂex  syncope  in  eight  patients.  Six
patients  in  the  ILR  group  and  two  in  the  conventional  group
received  a  pacemaker;  all  other  patients  received  drugs  or
counselling.  One  patient  died  during  follow-up;  this  death
Table  2  Causes  of  syncope  in  both  groups.
Cause  of  syncope  ILR  CONV  P
(n  =  39)  (n  =  39)
Certain
Vasovagal  4  (10)
Bradycardia  6  (15)
AV  block  2  (5)  1  (3)  1.0
SN  disease  4  (10)
Tachycardia  5  (13)
Atrial  ﬁbrillation  1  (2.5)
Ventricular  tachycardia  1  (2.5)
Other  3  (8)
Psychogenic  2  (5)
Non-syncopal  (epilepsy)  1  (3)
Supposed  8  (20)
Data are number (%). AV: atrioventricular; CONV: conventional
evaluation; ILR: implantable loop recorder; SN: sinus node.
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nas  due  to  acute  respiratory  failure  and  was  not  related  to
yncope.
The  number  of  hospitalization  days,  visits  and  tests  are
isted  in  Table  3. Patients  in  the  ILR  group  were  hospi-
alized  for  a  non-signiﬁcantly  shorter  period  than  patients
n  the  CONV  group:  5.7  ±  3.2  vs.  8.0  ±  1.4  days  (P  =  0.55).
he  numbers  of  GP  and  specialist  visits  indexed  by  patients
ere  similar  in  both  groups,  but  the  numbers  of  tests  done
uring  these  visits  were  lower  in  the  ILR  group  than  in
he  CONV  group:  0.1  ±  0.4  standard  cardiological  tests  per
atient  in  the  ILR  group  compared  with  0.3  ±  0.9  in  the
ONV  group  (P  =  0.8);  0.03  ±  0.2  advanced  cardiological  tests
er  patient  compared  with  0.2  ±  0.5  in  the  CONV  group
P  =  0.05).
QoL,  as  shown  by  the  results  of  the  SF-36  questionnaire
fter  14  months  of  follow-up,  was  not  different  in  the  ILR
roup  in  terms  of  the  physical  and  psychological  compo-
ents  (Table  4).  There  were  no  differences  between  the
ain  composite  scores  suggestive  of  general  physical  and
sychological  wellbeing.  While  there  were  no  differences
n  physical  functioning  (i.e.  intensity  of  exercise  or  walking
istance),  social  functioning  and  mental  health  between  the
wo  groups,  we  observed  a signiﬁcantly  better  score  in  ‘role
imitations  due  to  physical  problems’  (i.e.  unspeciﬁed  limi-
ation  of  any  kind  and  feeling  of  less  accomplishment)  in  the
LR  group.  The  scores  for  ‘role  limitations  due  to  emotional
roblems’  were  not  statistically  different  between  the  two
roups.
iscussion
he  main  results  of  the  study  are  that  the  early  use  of  an
LR  after  syncope,  in  the  context  of  the  French  healthcare
ystem,  allows  for  a  higher  number  of  certain  diagnoses
ompared  with  the  conventional  strategy.  This  higher  diag-
ostic  yield  is  obtained  along  with  a  reduction  in  the
umber  of  advanced  cardiological  tests  performed.  The
550  C.  Podoleanu  et  al.
Table  3  Clinical  events,  hospitalization  days,  visits  and  tests  that  occurred  during  the  14  months  of  follow-up.
ILR  CONV  P
(n  =  39)  (n  =  39)
Hospitalization  days  (n)  5.7  ±  3.2  8.0  ±  1.4  0.55
GP  visits  (n  per  patient)  1.3  ±  2.2  1.1  ±  3.2  0.1
Cardiologist  visits  (n  per  patient)  0.46  ±  1.5  0.47  ±  0.95  0.8
Neurologist  visits  (n  per  patient) 0.31  ±  0.9  0.06  ±  0.25  0.3
Other  specialist  visits  (n  per  patient) 0.15  ±  0.43 0.09  ±  0.4 0.4
Standard  cardiological  tests  (n  per  patient) 0.1  ±  0.4 0.3  ±  0.9 0.8
Advanced  cardiological  tests  (n  per  patient)  0.03  ±  0.2  0.2  ±  0.5  0.05
Neurological  tests  (n  per  patient)  0.05  ±  0.2  0.06  ±  0.3  0.85
Any  other  tests  (n  per  patient)  0.18  ±  0.8  0.09  ±  0.4  0.8
Syncope  recurrence  (n  per  patient)  0.46  ±  1.2  0.47  ±  1.5  0.6
Presyncope  recurrence  (n  per  patient)  1.2  ±  4.8  0.8  ±  2.5  0.7
Data are mean ± standard deviation. CONV: conventional evaluation; GP: general practitioner; ILR: implantable loop recorder.
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2LR  was  well  tolerated  in  terms  of  quality  of  life,  as  it
id  not  impair  the  physical  and  social  functioning  of  the
atients.
In  this  study,  we  followed  patients  with  severe  syncope
f  unknown  aetiology  after  initial  evaluation  and/or  atypi-
al  clinical  presentation  (absence  of  premonitory  signs  and
f  prodromal  symptoms).  In  these  patients,  the  underlying
echanism  of  the  syncope  needs  to  be  clariﬁed,  either  by
rolonged  monitoring  or  by  further  cardiological  examina-
ions,  including  provocative  tests  [1].  These  two  approaches
ay  either  delay  therapy  until  an  ECG  symptom  correlation
an  be  established  or  increase  the  number  of  tests  done
o  unmask  the  supposed  aetiology.  The  latter  approach  has
lso  the  disadvantage  of  leading  to  a  supposed  and  uncertain
etiology  [3].
In  our  study,  delayed  therapy  in  the  ILR  group  did  not
mpact  patient  outcome.  Only  one  patient  died  during
ollow-up  and  his  death  was  not  related  to  the  study  pro-
ocol.  The  number  of  syncope  recurrences  did  not  differ
etween  groups.  Similarly,  in  a  study  by  Farwell  et  al.,  there
ere  no  increases  in  the  numbers  of  subsequent  syncopal
pisodes  and  mortality  rates  in  patients  who  received  an
LR  [4].
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Table  4  SF-36  questionnaire  at  the  14-month  evaluation.
ILR  
(n  =  39)
Physical  functioning  69.2  ±  
Social  functioning  75.5  ±  
Role  limitation  (physical  problems)  61.3  ±  
Role  limitation  (emotional  problems)  73.1  ±  
Mental  health  60.6  ±  
Vitality  46.4  ±  
Pain  62.3  ±  
General  health  perception  56.1  ±  
Physical  composite  score  43.6  ±  
Psychological  composite  score 46.7  ±  
Data are mean ± standard deviation. CONV: conventional evaluation; ILThe  diagnostic  yield  of  the  ILR  in  our  study  was  46.2%  over
 period  of  14  months,  which  is  in  accordance  with  published
ata:  during  a  period  of  18  months,  the  diagnostic  yield  was,
n  average,  32%  and  increased  to  approximately  50%  when
he  monitoring  period  was  extended  to  two  years  [5].
The  higher  diagnostic  yield  of  the  early  use  of  an  ILR  is  in
ine  with  previous  studies.  A  single-centre  study  that  aimed
o  investigate  the  impact  of  ILRs  on  an  unselected  population
f  421  patients  presenting  acutely  for  syncope  showed  that
LR  signiﬁcantly  increased  the  rate  of  diagnosis  in  patients
ith  recurrent  syncope:  an  ECG  diagnosis  was  identiﬁed  in
3%  of  ILR  patients  compared  with  4%  of  patients  evaluated
onventionally  [4].
A  study  that  included  60  consecutive  patients  with  unex-
lained  syncope  randomized  to  conventional  testing  or  to
rolonged  monitoring  with  an  ILR,  showed  that  prolonged
onitoring  was  more  likely  to  result  in  a  diagnosis  than
onventional  testing.  A  diagnosis  was  obtained  in  14  of
7  patients  randomized  to  prolonged  monitoring  compared
ith  in  six  of  30  patients  undergoing  conventional  testing
52%  vs.  20%;  P  =  0.012)  [6].
In  the  present  study,  even  if  the  necessary  tests  were
ecided  upon  by  the  treating  physician,  there  were  fewer
CONV  P
 (n  =  39)
31.6  63.1  ±  31.3  0.27
24.6  78.2  ±  26.2  0.57
43.2  79.3  ±  33,4  0.05
42.5  82.8  ±  31.7  0.5
18.7  62.2  ±  17.6  0.79
18.6  52.9  ±  22.9  0.39
23.7  58.7  ±  27.9  0.61
16.0  63.0  ±  22.0  0.2
12.8  43.7  ±  8.7  0.82
11.3  46.6  ±  11.7  0.87
R: implantable loop recorder.
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REarly  use  of  an  implantable  loop  recorder  in  syncope  evalua
advanced  cardiological  tests  done  in  the  ILR  group  com-
pared  with  in  the  CONV  group.  As  these  tests  are  at  a  higher
cost,  our  study  suggests  that  the  ILR  strategy  decreases
the  cost  of  investigations  after  syncope.  Accordingly,  in  a
study  by  Farwell  et  al.,  ILR  patients  had  fewer  investiga-
tions  after  randomization  and  fewer  hospital  days,  resulting
in  a  cost  saving.  In  the  PICTURE  registry,  which  enrolled
570  patients,  the  median  number  of  tests  performed  per
patient  in  the  total  study  population  was  13;  the  tests
performed  most  frequently  were  echocardiography,  ECG,
ambulatory  ECG  monitoring,  in-hospital  ECG  monitoring,
exercise  testing  and  orthostatic  blood  pressure  measure-
ments  [7].  This  study  reported  a  high  diagnostic  yield
with  ILRs,  which  guided  the  diagnosis  in  78%  of  patients
with  recurrent  syncope  and  provided  useful  information  in
another  6%.
We did  not  observe  a  difference  in  duration  of  hospital-
ization  between  groups.  This  unexpected  result  probably
reﬂects  the  fact  that,  at  the  time  of  the  study,  the  eval-
uation  of  syncope  was  not  performed  on  an  outpatient
basis  in  most  cases.  We  hypothesize  that  the  length  of
hospital  stay  in  the  ILR  group  will  be  shorter  nowadays,
especially  as  very  small  insertable  devices  have  become
available.
A recent  study  assessed  the  efﬁcacy  of  a  standardized
care  pathway  approach  with  early  ILR  implantation,  based
on  European  Society  of  Cardiology  guidelines  [1],  compared
with  a  conventional  approach  in  a  high-volume  hospital  in
the  USA.  The  authors  found  that  by  using  a  standardized
approach  only  4%  of  patients  were  hospitalized,  compared
with  20%  in  the  conventional  group,  and  the  rate  of  diag-
nosis  at  45  days  was  greater  in  the  standardized  group
(57%  vs.  45%  in  the  total  population)  [1].  The  number  of
tests  or  consultations  associated  with  additional  charges
was  signiﬁcantly  lower  in  the  standardized  group  than  in
the  conventional  group  [8].  We  observed  a  similar  num-
ber  of  GP  and  non-cardiological  specialist  visits,  including
neurological  consultations,  in  both  groups,  which  reﬂects
the  variable  clinical  presentation  of  syncopal  episodes  that
can  be  frequently  misdiagnosed  as  neurological  disorders
[9].  Our  study  shows  that,  parallel  to  the  cardiological
assessment,  physicians  look  for  other  causes  of  loss  of  con-
sciousness.  Obviously,  the  early  ILR  strategy  could  not  affect
the  number  of  non-cardiological  investigations  and  visits.
QoL  was  assessed  using  the  SF-36  questionnaire  and
showed  that  ILR  had  no  signiﬁcant  negative  impact.  Earlier
studies  estimated  a  reduction  in  QoL  in  syncope  patients,
caused  mainly  by  the  fear  of  syncope  recurrence.  Given  that
the  incidence  of  recurrent  episodes  was  similar  in  the  both
groups,  it  is  not  surprising  that  there  were  no  differences
between  the  groups.  In  a  study  of  201  patients  who  received
an  ILR,  the  authors  reported  that  there  was  improved  QoL  in
the  ILR  group  for  general  wellbeing  using  the  SF-12  question-
naire  [10].  A  recently  published  trial  using  quality-adjusted
life-years  to  assess  the  cost-effectiveness  of  ILRs  in  people
with  transient  loss  of  consciousness  found  that  this  strategy
resulted  in  an  increased  gain  for  ILR  [11].Study limitations
The  limitations  of  our  study  result  from  the  small  number  of
patients  included;  this  was  due  to  the  relative  low  rate  of  ILR551
mplantations  and  poor  knowledge  of  this  diagnostic  tool  in
rance  during  the  study  period,  mainly  because  the  device
nd  implantation  were  not  reimbursed.  We  hope  that  such  a
tudy  may  help  to  increase  the  rate  of  implantation  of  ILRs
n  France.  Another  limitation  was  related  to  the  cost  of  the
evice,  which  was  not  taken  into  account  in  the  cost  analy-
is  because  it  was  heterogeneous  at  that  time  in  France.  A
urrent  evaluation  would  have  to  incorporate  this  cost  into
he  economic  analysis.
onclusion
n  patients  with  unexplained  syncope,  the  early  use  of  an
LR  has  a  superior  diagnostic  yield  compared  with  the  con-
entional  strategy,  with  lower  healthcare-related  costs.  Our
esults,  in  the  context  of  the  French  healthcare  system,
ay  encourage  better  reimbursement  of  the  device,  implan-
ation  procedure  and  follow-up  visits,  which,  in  turn,  may
ncrease  the  use  of  the  ILR,  as  recommended  by  the  guide-
ines  [1].
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